The expanded approval offers a significant boost for Jardiance, sales of which are already on track to top $1 billion this year. In the second quarter, revenue from the drug jumped 36% to about $357 million.

Lilly and Boehringer next have their eyes on approval for heart failure patients with preserved ejection fraction. The harder-to-treat condition occurs when the left ventricle can’t properly relax, resulting in the heart being unable to fill with enough blood to pump out to the body even though it’s still contracting normally.

Jardiance is the first medicine shown to reduce cardiovascular death and hospitalization for preserved ejection fraction patients in a late-stage study, according to Lilly. The company announced positive results from the trial in July, saying Jardiance showed a significant benefit, but didn’t give details. Researchers plan to present results at the European Society of Cardiology meeting later this month.

Read full story here.